• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1197576 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
2 ^; K; j2 I, l6 M( r7 X# I! E7 o4 GNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 6 `" L; R1 U& [
+ Author Affiliations  C- g( N2 D7 u. Q
, F9 v8 P( Z& I- f$ \" Q! t
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
4 y# h9 t2 r- N. ~2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
. a& @- ]2 _8 P3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan + s6 @: X( f1 F
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan . r' G# f' T2 d
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan + N: f1 Q# q" D8 M
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
7 E- c4 A6 F# Z- @" k3 e7Kinki University School of Medicine, Osaka 589-8511, Japan . n7 k* Y# ~$ R4 p- S
8Izumi Municipal Hospital, Osaka 594-0071, Japan
4 U1 N0 X9 v& L' Z- O9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
. U, G$ O2 u6 w" tCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp   ?: K# C  A/ N6 q. k. m
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
( [/ X# t" h4 V% B1 m
! U: u5 A1 D2 p6 f2 g
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
( {/ D/ \. s& `, @3 K# g- t6 J7 w; D2 p1 M9 E4 j9 @$ U' B: C
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
5 e, r& }$ b( k
; Y" D* G$ Z  o+ K6 tAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
9 X4 A* `, {6 ^1 E
# K! |7 r& I6 o- v- yPublished online on: Thursday, December 1, 2011 - v% b  v4 `0 [1 `& }

* E: j1 z3 P6 H+ J9 k7 R( `Doi: 10.3892/ol.2011.507   I2 [% G0 t  ?4 }- f! u
6 Z; x; x1 V' {- p
Pages: 405-410 7 A1 z" i' {) U  F

# G7 e7 \: @1 qAbstract:$ o0 S( f5 @- I8 l- i
S-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.2 t% W! M" E: u: B: p. L

$ I4 X) i/ F; j, E& j9 K7 b
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
8 R3 h) {, y* m6 m# u. P. l# r  KF. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 : `) `+ }" c: c7 R; E1 o
+ Author Affiliations
) x1 |, V& w! c1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu 4 V) g7 S% j  D7 A# j1 Y5 ]
2Department of Thoracic Surgery, Kyoto University, Kyoto 0 w! }$ f: Y# g
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
' U( D* P9 Q- l$ @% g" l. X% T&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
" |* X( w7 J2 B& U* q! G% ?5 U. @Received September 3, 2010.
  v" \0 \5 r  D+ v2 C% g4 U- B* zRevision received November 11, 2010. / d( a, o8 j2 |' d* z' e7 a- W
Accepted November 17, 2010.
/ |3 e3 [2 t) [0 i2 w% `; sAbstract
+ C# n$ `" J4 j5 ]Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
9 g: k- y/ ^' I& X3 w) k' R7 h6 YPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes. / H+ {  Y$ Z5 f' g+ A) v
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression. 3 V0 m/ t' ?5 H/ f/ K) Q/ C
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.   I2 A- @# G: K) R0 Q+ p3 a6 G% w
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
6 H& W6 |. D. s# i今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?" k- Q6 ^/ Y8 p1 O0 `
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
- k$ M' }/ N7 b4 I7 X7 L8 ?4 p* Ihttp://clinicaltrials.gov/ct2/show/NCT01523587
) u) o/ i& P) r' }. U6 x4 Z. A
7 R+ |! M- y: sBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
/ ~# z3 M2 O' A/ ^1 Y( jhttp://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 $ |8 P) F) @: T, `; M. S2 `' B
, M: E6 n8 |8 n6 i& E
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
$ }+ [, v/ U4 ]# B至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53
& h  i5 t, C+ g4 L  u从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。) g) Z% v% |7 `2 Y5 J
至今为止,未出 ...
) e, k4 \, @5 D" `7 g
没有副作用是第一追求,效果显著是第二追求。
6 @: {! d. m: x, o不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表